Robin Gustafsson (@MistralRobin) header
Robin Gustafsson (@MistralRobin) profile picture

democratizing luck

San Francisco, CA
Joined July 2016
Photo by Robin Gustafsson (@MistralRobin)Photo by Robin Gustafsson (@MistralRobin)Photo by Robin Gustafsson (@MistralRobin)Photo by Robin Gustafsson (@MistralRobin)Photo by Robin Gustafsson (@MistralRobin)Photo by Robin Gustafsson (@MistralRobin)Photo by Robin Gustafsson (@MistralRobin)Photo by Robin Gustafsson (@MistralRobin)Photo by Robin Gustafsson (@MistralRobin)Photo by Robin Gustafsson (@MistralRobin)
Robin Gustafsson retweeted
Nearly everyone I talk to thinks the world is going to be the same in 5-10 yrs ...that the human condition will be the same ...that the role of man and machine will be the same. What serenity these people must know... what peace. But ignorance will not long be bliss.
86
73
17
836
200,064
Robin Gustafsson retweeted
Universal High Income The most likely outcome
559
839
415
6,149
1,041,999
Robin Gustafsson retweeted
none of this shows up on a CV, yet it’s exactly what we love seeing.
4
7
36
996
Robin Gustafsson retweeted
Dusting off this tweet from April because this gap in shared understanding of LLM capability is *widening*. It's now less "two groups of people speaking past each other" and more a sharp funnel. - Napkin math somewhere around 6B people (~75% of the population) have barely come in contact with LLMs at all. - Around 1-2B (~20%) are casual and infrequent users of free-tier ChatGPT-like products. This group sees derpy chatbots and treats them a bit like a better Google search, a writing aid, or etc. Maybe an agent tries to book you a flight. I have non-tech friends who (reasonably, imo) say they have not much use for it at all. Even many professionals outside of math&code are in this tier. For example, execs and many other functions spend a lot of their time talking to other people, so while they understand what is happening intellectually, it is still second-hand and a bit abstract. - Now we get to professional use of frontier-grade LLMs in math&code. Somewhere around 20M people (0.2%) see first-hand that large, complex projects that used to take them weeks/months can now be completed by agents with a prompt. Building apps, copying apps, translating apps, decompiling apps from binaries... This has all happened very quickly and recently - less than 1 year ago, I was writing code manually by hand, typing memorized computer code commands into a code editor character by character, occasionally pressing Tab to autocomplete a little chunk of code. - And finally we get to the ~5,000 people (~0.00006%) with access to frontier-grade systems internally. The external world has seen the preview. It looks like swarms of thousands of agents collaborating over weeks on software mega projects: minting zero days, running cyber attacks and defenses at machine speeds, discovering new science, advancing the frontier of mathematics. Things that would have taken top professionals in the industry years of work. Meanwhile, human review and comprehension are starting to fall behind. For example, people are still involved in the "archeology" of the OpenAI-HF incident from many months ago. Mathematicians may be poring over the 722 manuscripts on frontier mathematics for a while. The funnel is driven by a combination of factors: 1. The impact scales with ambition, problem size, and horizon. A question with a paragraph answer barely stresses the system. You need a reservoir of big, difficult problems that you really care about. This aspect drives the consumer / professional dimension of the funnel. 2. The jaggedness of the system (which I have written about a lot separately). Capability peaks in domains that are digital, verifiable and economically valuable. This is because LLM capability emerges from reinforcement learning on verifiable rewards on a curated environment mixture driven by revenue potential. This aspect primarily drives the area (e.g. math&code) dimension of the funnel. 3. Access. Free-tier, paid-tier, internal. So this is the weirdness of the moment. The general public has mostly not interacted with these systems. When they have, it looks like a derpy chatbot. The majority of professionals still see only a modest uplift. And a small sliver of professionals are experiencing the vertigo of the curve going vertical. And it is all happening at the same time.
Judging by my tl there is a growing gap in understanding of AI capability. The first issue I think is around recency and tier of use. I think a lot of people tried the free tier of ChatGPT somewhere last year and allowed it to inform their views on AI a little too much. This is a group of reactions laughing at various quirks of the models, hallucinations, etc. Yes I also saw the viral videos of OpenAI's Advanced Voice mode fumbling simple queries like "should I drive or walk to the carwash". The thing is that these free and old/deprecated models don't reflect the capability in the latest round of state of the art agentic models of this year, especially OpenAI Codex and Claude Code. But that brings me to the second issue. Even if people paid $200/month to use the state of the art models, a lot of the capabilities are relatively "peaky" in highly technical areas. Typical queries around search, writing, advice, etc. are *not* the domain that has made the most noticeable and dramatic strides in capability. Partly, this is due to the technical details of reinforcement learning and its use of verifiable rewards. But partly, it's also because these use cases are not sufficiently prioritized by the companies in their hillclimbing because they don't lead to as much $$$ value. The goldmines are elsewhere, and the focus comes along. So that brings me to the second group of people, who *both* 1) pay for and use the state of the art frontier agentic models (OpenAI Codex / Claude Code) and 2) do so professionally in technical domains like programming, math and research. This group of people is subject to the highest amount of "AI Psychosis" because the recent improvements in these domains as of this year have been nothing short of staggering. When you hand a computer terminal to one of these models, you can now watch them melt programming problems that you'd normally expect to take days/weeks of work. It's this second group of people that assigns a much greater gravity to the capabilities, their slope, and various cyber-related repercussions. TLDR the people in these two groups are speaking past each other. It really is simultaneously the case that OpenAI's free and I think slightly orphaned (?) "Advanced Voice Mode" will fumble the dumbest questions in your Instagram's reels and *at the same time*, OpenAI's highest-tier and paid Codex model will go off for 1 hour to coherently restructure an entire code base, or find and exploit vulnerabilities in computer systems. This part really works and has made dramatic strides because 2 properties: 1) these domains offer explicit reward functions that are verifiable meaning they are easily amenable to reinforcement learning training (e.g. unit tests passed yes or no, in contrast to writing, which is much harder to explicitly judge), but also 2) they are a lot more valuable in b2b settings, meaning that the biggest fraction of the team is focused on improving them. So here we are.
2,266
5,942
2,297
44,378
7,019,743
Robin Gustafsson retweeted
Replying to @a16z
@a16z speedrun hackathon stats: > 3-person team > 3 hangovers > 300 agents > 0 bloat? @ToukoUrsin @marcsmeds @HackerSquad
32
18
1
31
679
Robin Gustafsson retweeted
Today we introduce Kairos 1: the world's first model built to simulate individual human behavior. Frontier models only understand population averages, ignoring the individual differences that make us human. Kairos beats Persimmon, Astra, Fable, and Gemini across 13 simulation benchmarks.
194
109
21
1,228
89,876
Robin Gustafsson retweeted
One year since pilot.
3
13
326
I've trained the fruit fly brain to generate misleading demos claiming to have trained the fly brain to drive cars, trade bitcoin, play beat saber and minecraft as a sociological study conducted by Harvard University. We are now complete with our study. Thank you for your time.
38
117
12
2,040
68,446
Robin Gustafsson retweeted
the single thing that would most accelerate our work at @ScienceCorp_ is a connectome the mouse is probably only ~$300M away, something highly worth funding
Introducing a complete map of the male fruit fly brain and central nervous system, created in partnership with @HHMIJanelia. With over 166,000 neurons, this is the largest cellular brain map to date. Learn more: goo.gle/4qQTtIW
29
69
3
877
66,837
Robin Gustafsson retweeted
you don't find out what you're capable of until someone next to you does something bigger. { } fellows, 2026 tally.so/r/pbRJGZ
2
4
15
428
Robin Gustafsson retweeted
Our viral 2-min video interviewing people from 2099 about how they see the time before aging was eradicated 🔮 Now on Youtube 🎬 Submitted to the #FutureVisionXPRIZE competition 💥 Wish us luck and let’s make this vision a reality 👇 youtu.be/vMy2H31RnLw?is=7wC9…
6
4
4
31
4,138
Robin Gustafsson retweeted
Vibe coders at 3am
253
2,220
267
32,668
1,051,159
Robin Gustafsson retweeted
What if we treated aging as an engineering problem? Stockholm Longevity × AI Hackathon 11–13 September. Epicenter Stockholm. Come build with us.
3
3
2
52
1,271
Robin Gustafsson retweeted
The world’s first anti-aging gene therapy has been injected into a human for the first time. In June 2026, Boston-based Life Biosciences announced that the first patient received a dose of their experimental therapy ER-100 in a Phase 1 clinical trial. The treatment uses partial epigenetic reprogramming by delivering three Yamanaka factors (OCT4, SOX2, and KLF4) to restore aged or damaged cells to a more youthful state. It is currently being tested as an injection into the eye for age-related optic neuropathies, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). This milestone marks the first time partial cellular reprogramming technology has been administered to a human. While the current trial focuses on safety and vision outcomes in the eye, it represents a major step toward broader anti-aging applications. [Life Biosciences. (2026). Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies. Company Press Release, June 9, 2026]
79
408
60
1,855
259,511
in case you're doubting how brutal the longevity biotech acceleration has been in the first half of 2026 here are a few signals: - Chai Discovery is reportedly raising $400M at a $3.4B valuation. AI-native biology is starting to command frontier-AI multiples - Verve Therapeutics triggered a ~$1B acquisition after demonstrating permanent cholesterol reduction via a single gene edit. One treatment. Lifelong effect - Retro Biosciences dosed the first humans with RTR242. a pill that reactivates the brain's cellular cleanup machinery. Sam Altman's bet on adding 10 healthy years to life. Phase 1 results Q3 - Junevity begins first-in-human trials H2 2026. their platform identified a novel target regulating chronic metabolic dysfunction. a natural GLP-1 alternative with no side effects - Life Biosciences injected the first ever reverse-aging drug into a human this week. three reprogramming genes delivered directly to aging cells. results by end of 2026 - David Sinclair just announced an oral reprogramming pill entering the $101M XPRIZE. not an injection. a pill you swallow. whole-body biological age reversal all of these converge in the same 6-month window this has never happened before in the history of longevity science the narrative is about to shift permanently bio/acc
16
80
5
580
29,923
Robin Gustafsson retweeted
Aging is the thing that kills people, not the late stage problems caused by aging. Remember, it's very hard to solve a problem without accurately naming it.
5
7
3
62
14,905
Robin Gustafsson retweeted
I’m excited to launch the Longevity Biotech Atlas, a personal project mapping 700+ organizations across the aging and longevity ecosystem. Longevity biotech is moving fast. A lot of the public narrative has centered on GLP-1s, peptides, biohacking, and consumer health optimization. But beneath that, a much deeper ecosystem is forming: companies, labs, investors, and non-profits working on core technologies that will enable fundamentally new forms of measurement and rejuvenation. The field is growing quickly, but it is still hard to answer basic questions: Who is building what? Which areas are crowded? Which technologies are underexplored? Where should founders, scientists, investors, and operators be paying attention? To help make the space easier to navigate, I synthesized public information on 700+ organizations—ranging from therapeutics developers, diagnostics, investors, and more— into a single database. You can explore the atlas at the link in the comments. This is still an early version, and I’ll be adding more over time: new organizations, personal accounts, bookmarks, and better ways to track how the field is evolving. My hope is to build this out into a core tool for people trying to understand, build, fund, or work in longevity. If you’re interested in aging biology, biotech, investing, company formation, or the future of medicine, follow along. I’ll be sharing updates, maps of different subfields, and analyses of where the biggest opportunities and gaps may be. Let me know what you find useful!
31
41
7
336
25,995
1/ You think longevity advice is gender-neutral. Kayla Barnes-Lentz will challenge that: female longevity has different constraints—hormones, cycles, fertility tradeoffs, and research gaps that change how you interpret data.
1
2
6
347
1/ @elainechenshi joined a classmate's MBA thesis project because he was her friend. When business school ended, he returned to the Air Force full-time. She kept going alone. 12 years later: BodySpec has served 300,000+ people.
1
3
5
429
1/ Dave Messina’s pattern interrupt: most health startups don’t die from bad science. They die in the last mile — workflow, incentives, reimbursement. Reality is the killer feature.
1
4
8
438